课题基金 / 基金详情

Effect of SGLT2 Inhibitors on Hepatic Glucose Metabolism: Role of Autonomic Nervous System

Effect of SGLT2 Inhibitors on Hepatic Glucose Metabolism: Role of Autonomic Nervous System
SGLT2 抑制剂对肝葡萄糖代谢的影响:自主神经系统的作用
批准号:
10218140
负责人:
Muhammad Abdul-Ghani
金额:
$60.44万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-21 至 2022-07-31

项目摘要

项目成果

Muhammad Abdul-Ghani的其他基金

相似基金

相关文献

中文摘要
翻译
钠-葡萄糖共转运抑制剂(SGLT2i)是一类新型的抗糖尿病药物
英文摘要
Sodium-Glucose cotransport inhibitors (SGLT2i) are a novel class of antidiabetic agents which lower the plasma glucose concentration by inhibiting renal glucose reuptake and producing glucosuria. In addition to lowering the plasma glucose concentration, members of this class exert multiple metabolic actions in T2DM all of which have significant clinical relevance and include: (1) stimulation of hepatic glucose production; (2) reduce fasting plasma insulin concentration and stimulate glucagon secretion, these hormonal changes were suggested to cause the increase in HGP; (3) inhibition of glucose oxidation; and (4) increase in fat oxidation and ketone production. Our preliminary data demonstrate that, in normal glucose tolerant individuals, SGLT2 inhibitors, stimulate glucose production, and cause significant increase in fat oxidation without a change in plasma glucose, insulin, glucagon and ketone concentrations. Further, SGLT2 inhibitors inhibited pyruvate oxidation in hepatocytes in culture. Based upon these novel findings, we hypothesize that, signals (likely neuronal) other than change in plasma insulin to glucagon ratio are activated by glucosuria and stimulate the increase in HGP in non-diabetic and likely in diabetic individuals as well. Further, we hypothesize that the increase in fat oxidation by SGLT2 inhibitors will depletes liver fat content in IFG and T2DM patients, increase hepatic glucose uptake and decrease the fasting plasma glucose concentration. To test these hypotheses, we will (1) Measure autonomic balance (with heart rate variability) and sympathetic nervous system activity (3H-norepinephrine turnover) in IFG, NGT and T2DM subjects (drug naïve with FPG <160 mg/dl) at baseline and at day 1 and 12 weeks of treatment with SGLT2 inhibitors, and (2) Measure FPG, bHGP (3H-glucose infusion), HGU (with Oral-IV double tracer infusion), whole body fat oxidation (indirect calorimetry), plasma insulin, glucagon, FFA, ketone and lactate concentrations, and hepatic fat content (1H-MRS) in IFG, NGT and T2DM patients (drug naïve with FPG <160 mg/dl) at baseline and at day 1 and 12 weeks after treatment with SGLT2 inhibitor
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Role of Glucose Mediated Glucose Uptake in the pathogenesis of IFG and IGT
The Role of Glucose Mediated Glucose Uptake in the pathogenesis of IFG and IGT
The Role of Glucose Mediated Glucose Uptake in the pathogenesis of IFG and IGT
The Role of Glucose Mediated Glucose Uptake in the pathogenesis of IFG and IGT
海外基金